All News

Simple changes to each day can improve motivation and wellness for pharmacists.

By using technology solutions, pharmacists can be further integrated into the care team.

Christine Walko, PharmD, BCOP, FCCP, discusses some new developments for PARP inhibitors in cancer care for patients with homologous recombination deficiency.

ProAir Digihaler Inhalation Powder is indicated for the treatment or prevention of bronchospasm in those with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Christopher Fine, MD, FACC, a cardiologist at National Jewish Health, discusses the relationship between heart disease and cancer and the importance of the field of cardio-oncology when treating patients with cancer.

In February of this year, the new statistics came out where we're at now 37 million with diabetes and 96 million with prediabetes.

Hypervitaminosis D, a condition characterized by elevated vitamin D levels, is associated with potential serious health issues, such as psychosis, abdominal pain, vomiting, pancreatitis, and renal failure.

The best thing for pharmacists to do during this time is provide unbiased, factually accurate information about this topic as a resource.

Findings suggest that the HER2 L755S mutation plays a role in the aggressiveness of lobular breast cancer observed in the clinic.

Autologous stem cell transplantation was underutilized in community settings for mantle cell lymphoma.

Tildrakizumab-asmn (Ilumya) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

BurnAid burn dressing provides relief for all types of minor burns.

Patient Centered Care is what should be at the heart of a pharmacist's work.

Survey results show 40% of health care leaders believe a lack of communication between prescribers and pharmacists is preventing the successful management of patients’ medications.

McKesson ideaShare 2022 is taking place in Washington, DC, from July 7 through 10.

The FDA approved a licensure request for Fluzone High-Dose Quadrivalent, Flublok Quadrivalent, and Fluzone Quadrivalent for use in the upcoming 2022-2023 flu season, providing influenza vaccination for adults 65 years of age and older.

People have been taking probiotics to support digestive health for centuries, but researchers in the pulmonary field have turned their attention toward how microbiome science can be used to support the lungs.

Brexpiprazole is indicated as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment in adults with schizophrenia.

Although treating mental health symptoms is essential, finding the time and energy for more appointments can be challenging for patients with cancer.

Trauma informed care has had an impact on the public health spectrum for years, especially with what has happened on a global front.

Paxlovid treats COVID-19 in adults and children [12 years of age and older weighing at least 88 pounds (40 kg)] with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Sacubitril and Valsartan (Entresto) is indicated to reduce the risk of cardiovascular death and hospitalization in adult patients with chronic heart failure.

Thrombocytopenia was the most common adverse effect, which was managed through dose reduction.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA; Alison Gulbis, PharmD, BCOP; and Kamakshi Rao, PharmD, BCOP, FASHP, discuss research conducted looking to assess the hematology-oncology pharmacist “great migration” from the field.

Isotretinoin exerts dose-dependent inhibition of sebaceous gland function, thereby reducing sebum secretion, which is associated with improvement in nodular acne.

Ken Thorpe, PhD, professor of public health at Emory University and chairman of Partnership to Fight Chronic Disease, discusses legislation that the US House of Representatives recently passed to put greater restrictions on the FDA’s accelerated approval pathway.

After 4 years of treatment with ofatumumab, 78.8% of patients with relapsing forms of multiple sclerosis who continuously received ofatumumab achieved NEDA-3 compared to 51.8% of those who switched from teriflunomide to ofatumumab.

Clinical trial results show durable responses with mosunetuzumab in advanced follicular lymphoma.

Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor that is not yet approved by any regulatory authority.

Jazz Pharmaceuticals announced top-line results from the phase 3 RELEASE MSS1 trial, evaluating nabiximols oromucosal spray in individuals with multiple sclerosis.